Skip to Content


Government-Owned Inventions; Availability for Licensing

Document Details

Information about this document as published in the Federal Register.

Published Document

This document has been published in the Federal Register. Use the PDF linked in the document sidebar for the official electronic format.

Start Preamble


National Institutes of Health, HHS.




The inventions listed below are owned by an agency of the U.S. Government and are available for licensing in the U.S. in accordance with 35 U.S.C. 209 and 37 CFR part 404 to achieve expeditious commercialization of federally-funded research and development. Foreign patent applications are filed on selected inventions to extend market coverage for companies and may also be available for licensing.

Start Further Info


Licensing information and copies of the U.S. patent applications listed below may be obtained by writing to the indicated licensing contact at the National Heart, Lung and Blood Institute, Office of Technology Transfer and Development, National Institutes of Health, 31 Center Drive Room 4A29, MSC2479, Bethesda, MD 20892-2479; telephone: 301-402-5579. A signed Confidential Disclosure Agreement may be required to receive copies of the patent applications.

End Further Info End Preamble Start Supplemental Information


Technology descriptions follow.

Methods for Artificial Oocyte Activation

Description of Technology

Available for licensing and commercial development for both human and veterinary uses is a method of activating mammalian oocytes. These methods include contacting a mammalian oocyte of interest arrested at metaphase II with an effective amount of a Regulator of G-Protein Signaling (RGS)2 inhibitor; and contacting the mammalian oocyte of interest with an effective amount of a G protein coupled receptor activator. In general, RGS proteins stimulate the hydrolysis of GTP bound to activated Gα subunits, leading to signal termination. RGS2, which inhibits both G-αq and G-αs signaling suppresses Ca2+ release in mature mammalian eggs. Regulators of G-Protein Signaling (RGS)2 inhibitor and a G protein coupled receptor activator can be used to artificially activate a mammalian oocyte such that it re-enters the cell cycle. Examples of RGS2 inhibitors can be nucleic acids like siRNAs or dsRNAs. G-protein coupled receptor activators can be acetylcholine, a neurotransmitter such as serotonin, hormones, natural or synthetic G Start Printed Page 76373protein coupled receptor ligands or modulator, and acidic pH. The oocyte can be fertilized in vitro to form an embryo, which can be implanted in a subject and developed to term or can be used for the preparation of stem cells.

Potential Commercial Applications

  • in vitro fertilization

Development Stage

  • Early Stage

Inventors: Miranda L. Bernhardt, Carmen J. Williams, Andres Gambini (all of NIEHS), and Lisa M. Mehlmann (University of Connecticut).

Intellectual Property: HHS Reference No. E-253-2016/0.

  • U.S. Provisional Patent Application No. 62/405,803 filed 7 October 2016.

Licensing Contact: Michael Shmilovich, Esq, CLP; 301-435-5019;

Start Signature

Dated: October 24, 2016.

Michael Shmilovich,

National Heart, Lung and Blood Institute, Office of Technology Transfer and Development, National Institutes of Health.

End Signature End Supplemental Information

[FR Doc. 2016-26390 Filed 11-1-16; 8:45 am]